ConductScience.org, home

Paper38540673

Treatment Strategies for Anti-VEGF Resistance in Neovascular Age-Related Macular Degeneration by Targeting Arteriolar Choroidal Neovascularization.

Fu Y and 3 others. Biomolecules, 2024. Cited by 33 papers, by iCite.

Cite this record

ConductScience Library. Treatment Strategies for Anti-VEGF Resistance in Neovascular Age-Related Macular Degeneration by Targeting Arteriolar Choroidal Neovascularization. Papers, record 38540673. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38540673

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Treatment Strategies for Anti-VEGF Resistance in Neovascular Age-Related Macular Degeneration by Targeting Arteriolar Choroidal Neovascularization.
PubMed
Journal
Biomolecules
PubMed
Year
2024
PubMed
Publication types
Journal Article, Review, Research Support, U.S. Gov't, Non-P.H.S., Research Support, N.I.H., Extramural
PubMed
Citations, by iCite
33
iCite
Relative citation ratio, by iCite
7.52, provisional
iCite
Revised in PubMed
2026-09-30
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Fu YYingbin
2Zhang ZZhao
3Webster KAKeith A
4Paulus YMYannis M

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Macular DegenerationMajor topic
Choroidal NeovascularizationMajor topic
Animals
Humans
Angiogenesis Inhibitors
Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factors
Cholesterol

Source PubMed

Download CSV of topics

Grants6

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
R01 EY034325NEI NIH HHSUnited StatesR01EY034325PubMed and NIHNIH RePORTER
R01 EY033000NEI NIH HHSUnited StatesR01EY033000PubMed and NIHNIH RePORTER
P30 EY002520NEI NIH HHSUnited StatesP30EY002520PubMed and NIHNIH RePORTER
P30 EY007003NEI NIH HHSUnited StatesP30EY007003PubMedNIH RePORTER
1R01EY033805 1R01EY034325 1R01EY033000 2P30EY002520 P30 EY007003NIH HHSUnited StatesR01EY033805PubMed and NIHNIH RePORTER
R01 EY033805NEI NIH HHSUnited StatesR01EY033805PubMed and NIHNIH RePORTER

Download CSV of grants

References127

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
132428913Meta-Analysis of the Pharmacogenetics of ARMS2 A69S Polymorphism and the Response to Advanced Age-Related Macular Degeneration.Ophthalmic Res2021https://conductscience.org/library/papers/32428913PubMed
231288022Real-time OCT guidance and multimodal imaging monitoring of subretinal injection induced choroidal neovascularization in rabbit eyes.Exp Eye Res2019https://conductscience.org/library/papers/31288022PubMed
331862695Lipid rafts in glial cells: role in neuroinflammation and pain processing.J Lipid Res2020https://conductscience.org/library/papers/31862695PubMed
410534470Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice.Circulation1999https://conductscience.org/library/papers/10534470PubMed
525166908Endothelium in spots--high-content imaging of lipid rafts clusters in db/db mice.PLoS One2014https://conductscience.org/library/papers/25166908PubMed
630649077RATES OF EXUDATIVE RECURRENCE FOR EYES WITH INACTIVATED WET AGE-RELATED MACULAR DEGENERATION ON 12-WEEK INTERVAL DOSING WITH BEVACIZUMAB THERAPY.Retina2020https://conductscience.org/library/papers/30649077PubMed
730849371VEGF in Signaling and Disease: Beyond Discovery and Development.Cell2019https://conductscience.org/library/papers/30849371PubMed
827330279Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review.Drug Des Devel Ther2016https://conductscience.org/library/papers/27330279PubMed
920920825Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials.Ophthalmology2011https://conductscience.org/library/papers/20920825PubMed
1023901256Initial non-responders to ranibizumab in the treatment of age-related macular degeneration (AMD).Clin Ophthalmol2013https://conductscience.org/library/papers/23901256PubMed
1124144450Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration.Ophthalmology2014https://conductscience.org/library/papers/24144450PubMed
1223719382Control of angiogenesis by AIBP-mediated cholesterol efflux.Nature2013https://conductscience.org/library/papers/23719382PubMed
1327500363Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs.J Vis Exp2016https://conductscience.org/library/papers/27500363PubMed
1420559689Immunohistochemical study of the growth factors, aFGF, bFGF, PDGF-AB, VEGF-A and its receptor (Flk-1) during arteriogenesis.Mol Cell Biochem2010https://conductscience.org/library/papers/20559689PubMed
1534403208Genetic associations of anti-vascular endothelial growth factor therapy response in age-related macular degeneration: a systematic review and meta-analysis.Acta Ophthalmol2022https://conductscience.org/library/papers/34403208PubMed
1630844038Association of CD11b+ Monocytes and Anti-Vascular Endothelial Growth Factor Injections in Treatment of Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy.JAMA Ophthalmol2019https://conductscience.org/library/papers/30844038PubMed
1726614117Macrophages: An Inflammatory Link Between Angiogenesis and Lymphangiogenesis.Microcirculation2016https://conductscience.org/library/papers/26614117PubMed
1828061854Association of statin use and hypertriglyceridemia with diabetic macular edema in patients with type 2 diabetes and diabetic retinopathy.Cardiovasc Diabetol2017https://conductscience.org/library/papers/28061854PubMed
1930135304AIBP augments cholesterol efflux from alveolar macrophages to surfactant and reduces acute lung inflammation.JCI Insight2018https://conductscience.org/library/papers/30135304PubMed
204039560Cellular mechanisms of resolution of drusen after laser coagulation. An experimental study.Arch Ophthalmol1985https://conductscience.org/library/papers/4039560PubMed

See all 127 referencesDownload CSV of references

Cited by28

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 33 citations.

PMIDTitleJournalYearIn PapersSource
42799766Novel semi-automated system for multi-dimensional analysis of macular neovascularization: quantitative biomarkers and rule-based morphological categorization across OCTA platforms.Graefes Arch Clin Exp Ophthalmol2026https://conductscience.org/library/papers/42799766PubMed
42792595Fluid Shear Stress Drives Endothelial Glycolytic Reprogramming via an AIBP/VEGF Axis.Biology (Basel)2026https://conductscience.org/library/papers/42792595PubMed
42775202The CD39-CD73-adenosine axis: a pivotal regulator of retinal homeostasis and diseases.Front Cell Dev Biol2026https://conductscience.org/library/papers/42775202PubMed
42352241Ocular Safety of Intravitreal Engineered Humanized Anti-VEGF Nanobody and Its Efficacy in the Attenuation of Choroidal Neovascularization and Associated Subretinal Fibrosis.Biomolecules2026https://conductscience.org/library/papers/42352241PubMed
42335286Nocturnal Intraocular Pressure Monitoring With a Soft Contact Lens Sensor for Glaucoma Management.Adv Mater2026https://conductscience.org/library/papers/42335286PubMed
42321788A novel Tie2xVEGF bispecific antibody fusion demonstrates enhanced therapeutic efficacy through direct Tie2 activation and VEGF neutralization.J Transl Med2026https://conductscience.org/library/papers/42321788PubMed
42217724Murine models of neovascular AMD revisited: Mechanistic pathways, immune-metabolic crosstalk, and the impact of aging and sex.Exp Eye Res2026https://conductscience.org/library/papers/42217724PubMed
42080790Suboptimal Responses to Anti-VEGF in Retinal Neurovascular Diseases: Linking Aging and Alternative Angioinflammatory Pathways.Invest Ophthalmol Vis Sci2026https://conductscience.org/library/papers/42080790PubMed
42012273Safety and Efficacy of cceAAV-aflibercept-Fc-YTE (F-CRG-B191): A Gene Therapy for Neovascular Age-Related Macular Degeneration.Invest Ophthalmol Vis Sci2026https://conductscience.org/library/papers/42012273PubMed
41658807Expert Opinion on the First-Line Management of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema in India: The Role of Faricimab.Cureus2026https://conductscience.org/library/papers/41658807PubMed
41603251DNA Nanoflower LYTACs Enable Efficient VEGF Degradation and Verteporfin Loading for Combined Therapy of Wet Age-Related Macular Degeneration.Adv Sci (Weinh)2026https://conductscience.org/library/papers/41603251PubMed
41373488Retinal Organoid-Derived Exosomes Reduce CNV Lesion and Restore RPE Integrity in Mouse Laser-Induced Choroidal Neovascularization (CNV) Model.Int J Mol Sci2025https://conductscience.org/library/papers/41373488PubMed
41143143Faricimab for Refractory Neovascular Age-Related Macular Degeneration: Retrospective Real-World Evidence from India.Clin Ophthalmol2025https://conductscience.org/library/papers/41143143PubMed
40943417From Pathophysiology to Innovative Therapies in Eye Diseases: A Brief Overview.Int J Mol Sci2025https://conductscience.org/library/papers/40943417PubMed
40875052Morphologic changes of the double-layer sign during anti-vascular endothelial growth factor therapy in eyes with neovascular age-related macular degeneration.Int Ophthalmol2025https://conductscience.org/library/papers/40875052PubMed
40850787Pharmacoproteomics in the development of personalised medicine in Age-related Macular Degeneration (PHARPRO-AMD) study protocol.BMJ Open Ophthalmol2025https://conductscience.org/library/papers/40850787PubMed
40730279Multimodal retinal imaging evaluation of macular degeneration persistent disease activity animal model in Watanabe heritable hyperlipidemic rabbits.Exp Eye Res2025https://conductscience.org/library/papers/40730279PubMed
40718797Targeting retinal angiogenesis: sex differences in adverse reactions to anti-VEGF therapies.Ther Adv Ophthalmol2025https://conductscience.org/library/papers/40718797PubMed
40710360The Long-Standing Problem of Proliferative Retinopathies: Current Understanding and Critical Cues.Cells2025https://conductscience.org/library/papers/40710360PubMed
40684186Recent advances in engineered exosome-based therapies for ocular vascular disease.J Nanobiotechnology2025https://conductscience.org/library/papers/40684186PubMed

See all 28 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
VEGFA7422PubTator's text mininghttps://conductscience.org/library/genes/7422

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/38540673

GET https://conductscience.org/api/papers/v1/38540673/references?page=2